Published online before print February 28, 2008, doi: 10.1161/CIRCRESAHA.107.165530
© 2008 American Heart Association, Inc.
Molecular Medicine |
Bone Morphogenetic Protein-9 Is a Circulating Vascular Quiescence Factor
From the Institut National de la Santé et de la Recherche Médicale (L.D., C.M., M.K., J.-J.F., S.B.), U878, Grenoble; Commissariat à l’Energie Atomique (L.D., C.M., M.K., J.-J.F., S.B.), Institut de Recherches en Technologies et Sciences pour le Vivant/Laboratoire Angiogenèse et Physiopathologie Vasculaire, Grenoble; Université Joseph Fourier (L.D., C.M., M.K., J.-J.F., S.B.), Grenoble; Institut National de la Santé et de la Recherche Médicale (N.L., J.-M.G.), Unité 833, Collège de France, Paris; Hospices Civils de Lyon (S.D.-G., H.P.); Hôpital Hôtel-Dieu (S.D.-G., H.P.), Lyon; and Département de Génétique Clinique and Centre National de Réference pour la maladie de Rendu-Osler (S.D.-G., H.P.), Lyon, France.
Correspondence to Sabine Bailly, U878, iRTSV/LAPV, 17 rue des Martyrs, 38054 Grenoble, France. E-mail sbailly{at}cea.fr
Angiogenesis is a complex process, requiring a finely tuned balance between numerous stimulatory and inhibitory signals. ALK1 (activin receptor like-kinase 1) is an endothelial-specific type 1 receptor of the transforming growth factor-β receptor family. Heterozygotes with mutations in the ALK1 gene develop hereditary hemorrhagic telangiectasia type 2 (HHT2). Recently, we reported that bone morphogenetic protein (BMP)9 and BMP10 are specific ligands for ALK1 that potently inhibit microvascular endothelial cell migration and growth. These data lead us to suggest that these factors may play a role in the control of vascular quiescence. To test this hypothesis, we checked their presence in human serum. We found that human serum induced Smad1/5 phosphorylation. To identify the active factor, we tested neutralizing antibodies against BMP members and found that only the anti-BMP9 inhibited serum-induced Smad1/5 phosphorylation. The concentration of circulating BMP9 was found to vary between 2 and 12 ng/mL in sera and plasma from healthy humans, a value well above its EC50 (50 pg/mL). These data indicated that BMP9 is circulating at a biologically active concentration. We then tested the effects of BMP9 in 2 in vivo angiogenic assays. We found that BMP9 strongly inhibited sprouting angiogenesis in the mouse sponge angiogenesis assay and that BMP9 could inhibit blood circulation in the chicken chorioallantoic membrane assay. Taken together, our results demonstrate that BMP9, circulating under a biologically active form, is a potent antiangiogenic factor that is likely to play a physiological role in the control of adult blood vessel quiescence.
Key Words: BMP9 • ALK1 • HHT • angiogenesis
This article has been cited by other articles:
 |
|
 |
|
  P. D. Upton, R. J. Davies, R. C. Trembath, and N. W. Morrell Bone Morphogenetic Protein (BMP) and Activin Type II Receptors Balance BMP9 Signals Mediated by Activin Receptor-like Kinase-1 in Human Pulmonary Artery Endothelial Cells J. Biol. Chem., June 5, 2009; 284(23): 15794 - 15804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. De Smet, I. Segura, K. De Bock, P. J. Hohensinner, and P. Carmeliet Mechanisms of Vessel Branching: Filopodia on Endothelial Tip Cells Lead the Way Arterioscler. Thromb. Vasc. Biol., May 1, 2009; 29(5): 639 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Fukuda, M. Kohda, K. Kanomata, J. Nojima, A. Nakamura, J. Kamizono, Y. Noguchi, K. Iwakiri, T. Kondo, J. Kurose, et al. Constitutively Activated ALK2 and Increased SMAD1/5 Cooperatively Induce Bone Morphogenetic Protein Signaling in Fibrodysplasia Ossificans Progressiva J. Biol. Chem., March 13, 2009; 284(11): 7149 - 7156. [Abstract] [Full Text] [PDF]
|
|